Gillead Sciences, the biopharmaceutical american that manufactures the remdesivir (antiviral that has been shown to be beneficial in the treatment of patients with covid-19), revealed in an open letter-published on Monday – the price of the drug.
For the united States and developed countries, each bottle of remdesivir will cost 390 usd (about 320 thousand chilean pesos). Based on the patterns of treatment -with a duration of five days, in each patient should be six bottles, which equates to 2,340 usd per person (1.9 million pesos approximately).
“Part of the intent behind our decision was to eliminate the need for rate negotiations, country by country. Discounted price to a level that is affordable to the developed countries with the purchasing power lower. This price will be offered to all the governments of the developed countries around the world where remdesivir is approved or licensed for its use,” noted the executive director of Gillead Sciences, Daniel O’day, in the open letter.
For private insurance companies of EE.US, the price of the bottle will be 520 dollars ($425 thousand pesos), i.e., 3,120 needy dollars per treatment (2.5 million pesos).
In developing countries, the company has signed agreements with manufacturers of generic drugs to facilitate treatment of the lower cost.
The remdesivir, which is administered by the intravenous route, is the first drug authorized by the Food and Drug Administration of Usa (FDA, for its acronym in English) to treat patients with covid-19.
A few days ago, the European medicines Agency (EMA) recommended the marketing of the drug. As in EE.US, the remdesivir has been the first drug in a pass evaluation of the european agency. Yes, the last word will be the European Commission.
A study developed by the National Institute of Allergy and Infectious Diseases (NIAID) of EE.USA, and published may 22 in the New England Journal of Medicine, revealed that the drug accelerated the recovery of patients hospitalzados by covid-19.
The institute conducted clinical trials in more than a thousand patients, distributed in 75 hospitals of different countries. The people who received remdesivir recovered on average a 31% faster than the rest. The average period of recovery was reduced from 15 to 11 days.